USPH

Business Context and Reporting Period

Company: U.S. Physical Therapy, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2001
Business Overview: The Company operates 162 outpatient physical and occupational therapy clinics across 31 states, providing post-operative care, orthopedic treatment, and rehabilitation services. Revenue is primarily derived from commercial health insurance, workers' compensation, managed care, and Medicare. The Company utilizes a partnership model where managing therapists often hold equity interests in their respective clinics.

Key Financial Metrics

Note: Per share data reflects adjustments for a 2-for-1 stock split in Jan 2001 and a 3-for-2 stock split in June 2001.

Material Changes vs. Prior Period

• Revenue Growth: Net revenues increased 28% to $80.9 million, driven by a 25% increase in patient visits (871,000 visits) and the addition of 30 new clinics. Mature clinics contributed $14.1 million of the revenue increase.
• Profitability: Net income nearly doubled to $7.1 million (up 89%). Operating margins improved as clinic operating costs decreased as a percentage of revenue from 72% in 2000 to 68% in 2001.
• Debt Reduction: Long-term debt decreased significantly from $7.2 million to $3.0 million. This was primarily due to the conversion of $4.2 million in convertible subordinated notes into common stock in early 2001, eliminating associated interest expenses.
• Liquidity: Cash and cash equivalents increased by $6.1 million to $8.1 million, bolstered by strong operating cash flows and proceeds from stock option exercises.
• Acquisitions: The Company purchased minority interests in 13 Michigan clinics during 2001, issuing stock and notes payable as partial consideration.

Outlook, Risks, and Management Commentary

• Guidance: Management plans to open between 35 and 40 new clinics in 2002. They anticipate that new clinics will initially operate at lower margins due to start-up costs but will favorably impact results in subsequent years.
• Regulatory Risks: The Company faces significant regulatory exposure regarding Medicare reimbursement limits ($1,500 per patient annually), though a moratorium on this limit was extended through 2002. Compliance with the Fraud and Abuse Law and Stark Law regarding physician referrals and facility management contracts remains a critical risk.
• Convertible Debt: $3.0 million of Series C Convertible Subordinated Notes remain outstanding. Based on stock prices in March 2002, the fair value of these notes was estimated at $16.1 million, suggesting a high likelihood of future conversion.
• Accounting Changes: The Company adopted SFAS 141 and SFAS 142 in 2001/2002, which impacts the accounting for business combinations and the amortization of goodwill (goodwill is no longer amortized but tested for impairment).

Investor Verification Checklist

• Medicare Reimbursement: Verify the status of the moratorium on the $1,500 annual therapy cap and potential impacts on 2003 revenue if the limit is reinstated.
• Debt Conversion: Confirm the conversion status of the remaining $3.0 million Series C Notes and the potential dilution to existing shareholders.
• Goodwill Impairment: Monitor the impact of SFAS 142 adoption on the $4.5 million in unamortized goodwill and potential future impairment charges.
• Regulatory Compliance: Review any updates regarding investigations or audits related to the Fraud and Abuse Law and Stark Law, particularly concerning the management of physician-owned facilities.
• Minority Interest Distributions: Assess the cash flow impact of distributions to minority partners in subsidiary limited partnerships, which totaled $4.5 million in 2001.